Search companies

Live

CONTROL BIONICS LIMITED (ASX: CBL)

Health care · News and insights

CBL: $0.048 -5.88% · MC: $29M

Latest CBL announcements

Announcement Insights

Control Bionics Reaffirms FY27 Growth Outlook as NeuroStrip Reaches Four-Market Registration

Control Bionics reaffirmed its outlook for approximately 50% revenue growth in FY27, weighted to the second half, after unaudited revenue rose each month in the September quarter and exceeded the June quarter. The company said its current plan is funded through FY27 without another capital raising, with about $6 million in cash at quarter-end and a material reduction in operating cash outflows forecast for the next quarter. NeuroStrip’s Australian registration completes its rollout across four markets, shifting the company’s focus to securing customers and partners.

Updated 17 Nov 2026, 09:27 AM Sydney time
Share
SourcesNeuroStrip registered as a Medical Device in AustraliaChange of Director's Interest Notice - SteeleLetter to Shareholders Bell Potter ConferenceChange of Director's Interest Notice - RixLess Than Marketable Parcel Sale FacilityQuarterly Activities/Appendix 4C Cash Flow Report
Comments

Control Bionics Wins Australian Registration for NeuroStrip, Completing Four-Market Rollout

2026-11-17 · Health care

CBL: $0.048 -5.88% · MC: $29M

Control Bionics’ NeuroStrip wearable device has been included on Australia’s medical device register as a Class I device, allowing the company to supply it locally. The registration adds Australia to the US, Great Britain and European markets where NeuroStrip is already registered; the company says its focus is now on winning customers and partners.

Updated 2026-11-17 09:17
Share
SourcesNeuroStrip registered as a Medical Device in Australia
Comments

Control Bionics Director Adds to Shareholding With On-Market Purchase

2026-10-30 · Health care

CBL: $0.052 +6.12% · MC: $29M

Control Bionics director Stephen Rix acquired one million shares on market, increasing his direct and indirect holding to 11 million shares. The purchase follows a separate company update reporting revenue growth through the September quarter and reaffirming expected revenue growth of 50% in FY27, weighted to the second half.

Updated 2026-10-30 13:29
Share
SourcesChange of Director's Interest Notice - Rix
Comments

Control Bionics Reports Revenue Growth, Reaffirms 50% FY27 Growth Outlook

2026-10-29 · Health care

CBL: $0.049 +0.00% · MC: $29M

Control Bionics said unaudited revenue rose each month in the September quarter and exceeded the June quarter, while it expects revenue growth of approximately 50% in FY27, weighted to the second half. Quarterly operating cash outflows included FY26 incentives and other one-off costs, with the company forecasting a material reduction in the next quarter; it reported cash at bank of approximately $6 million at quarter end and said its current plan funds operations through FY27 without another capital raising. Separately, it established a facility for eligible small shareholders to sell their holdings without brokerage or handling fees, with the company covering transaction costs.

Updated 2026-10-29 11:04
Share
SourcesLess Than Marketable Parcel Sale FacilityQuarterly Activities/Appendix 4C Cash Flow Report
Comments